Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17036
Country/Region: South Africa
Year: 2016
Main Partner: Foundation for Professional Development
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $19,098,335 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $3,241,153
Care: TB/HIV (HVTB) $2,488,348
Care: Pediatric Care and Support (PDCS) $578,514
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,157,028
Treatment: Adult Treatment (HTXS) $11,054,778
Treatment: Pediatric Treatment (PDTX) $578,514
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 59,174
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 39,453
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 330,122
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 223,132
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 657,598
HTS_TST Service Delivery Point (Facility): Inpatient 2017 15,929
HTS_TST Service Delivery Point (Facility): Outpatient 2017 1,927
HTS_TST Service Delivery Point (Facility): Outpatient 2017 387,778
HTS_TST Service Delivery Point (Facility): Pediatric 2017 578
HTS_TST Service Delivery Point (Facility): Pediatric 2017 74,421
HTS_TST Service Delivery Point (Facility): PMTCT 2017 174,293
HTS_TST Sum of Aggregated Age/Sex <15 2017 98,627
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 553,254
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 651,881
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 9,180
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 35
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 5,010
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 42,220
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 28,203
PMTCT_ART Already on ART at beginning of current pregnancy 2017 8,825
PMTCT_ART New on ART 2017 6,223
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 98,298
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 16
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 14,879
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 62
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 10
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 128
PMTCT_EID Sum of Infant Age disaggregates 2017 16
PMTCT_EID Sum of Infant Age disaggregates 2017 14,941
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 203
PMTCT_STAT By: Known positives at entry 2017 39,317
PMTCT_STAT By: Number of new positives identified 2017 58,913
PMTCT_STAT Number of new ANC and L&D clients 2017 100,282
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 98,298
PMTCT_STAT Sum of Positives Status disaggregates 2017 98,230
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 691
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3,405
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,089
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3,200
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 9,241
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 8,401
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 9,253
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 3
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 462
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 922
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 7,866
TB_SCREENDX Screen Result: Screened Positive for TB 2017 10,286
TB_SCREENDX Screen Results: Screened Positive for TB 2017 104
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 1
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 5,140
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 3,432
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 906
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 607
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 506,060
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,357
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 7,732
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 915
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 5,229
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 15,175
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 16,025
TX_CURR Aggregated Age/Sex: <15 Female 2017 41,968
TX_CURR Aggregated Age/Sex: <15 Male 2017 27,982
TX_CURR Aggregated Age/Sex: 15+ Female 2017 237,873
TX_CURR Aggregated Age/Sex: 15+ Male 2017 351
TX_CURR Aggregated Age/Sex: 15+ Male 2017 158,510
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 466,368
TX_CURR Sum of Aggregated Age/Sex <15 2017 69,950
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 351
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 396,383
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 351
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 466,333
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 37
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 18,116
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 12,532
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 102,651
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 67,384
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 204,313
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 37
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 200,683
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 422,305
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 379,114
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 34,620
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 23,196
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 499
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 192,661
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 129,789
TX_PVLS Numerator: Indication: Routine 2017 330,936
TX_PVLS Numerator: Indication: Targeted 2017 38,313
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 5,791
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3,857
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 499
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 32,796
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 21,861
TX_PVLS_den Denominator: Indication: Routine 2017 61,970
TX_PVLS_den Denominator: Indication: Targeted 2017 6,885
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 21,683
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 14,457
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 122,838
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 81,935
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 241,089
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 261,785
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,773
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 13
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,516
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 21,398
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 76
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14,264
Cross Cutting Budget Categories and Known Amounts Total: $200,000
Human Resources for Health $120,000
Gender: Gender Based Violence (GBV) $80,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation